Silent myocardial ischemia. A clinical perspective

Area of Science:

• Cardiology
• Ischemic Heart Disease

Background:

• Silent myocardial ischemia is more prevalent than symptomatic angina in coronary artery disease (CAD).
• Both increased myocardial oxygen demand and coronary vasomotor tone abnormalities contribute to silent ischemia.
• Over 40% of stable angina patients experience frequent silent ischemic episodes.

Purpose of the Study:

• To evaluate the role of silent ischemia in patients with coronary artery disease.
• To assess the impact of silent ischemia on adverse cardiac events and mortality.
• To determine if anti-ischemic therapy targeting total ischemic burden improves prognosis.

Main Methods:

• Review of recent data on silent myocardial ischemia prevalence in CAD.
• Analysis of factors contributing to the genesis of silent ischemia.
• Evaluation of studies on anti-ischemic drug efficacy in reducing silent ischemic episodes and their prognostic impact.

Main Results:

• Silent myocardial ischemia occurs frequently in CAD, exceeding anginal episodes.
• The presence of silent ischemia is a predictor of increased risk for coronary events and cardiac death.
• While anti-ischemic drugs reduce silent ischemia duration and frequency, no study has shown improved prognosis.

Conclusions:

• Silent myocardial ischemia is a significant clinical issue in CAD with prognostic implications.
• Therapeutic strategies should consider controlling the total ischemic burden.
• Current anti-ischemic treatments effectively reduce silent ischemia burden but lack proven prognostic benefit.